HomeCompareBVNRY vs NOBL

BVNRY vs NOBL: Dividend Comparison 2026

BVNRY yields 20.15% · NOBL yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BVNRY wins by $506.00 in total portfolio value
10 years
BVNRY
BVNRY
● Live price
20.15%
Share price
$9.93
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.3K
Annual income
$2.34
Full BVNRY calculator →
NOBL
NOBL
● Live price
2.14%
Share price
$106.01
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.8K
Annual income
$246.19
Full NOBL calculator →

Portfolio growth — BVNRY vs NOBL

📍 BVNRY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBVNRYNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BVNRY + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BVNRY pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BVNRY
Annual income on $10K today (after 15% tax)
$1,712.85/yr
After 10yr DRIP, annual income (after tax)
$1.99/yr
NOBL
Annual income on $10K today (after 15% tax)
$182.19/yr
After 10yr DRIP, annual income (after tax)
$209.26/yr
At 15% tax rate, NOBL beats the other by $207.27/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BVNRY + NOBL for your $10,000?

BVNRY: 50%NOBL: 50%
100% NOBL50/50100% BVNRY
Portfolio after 10yr
$23.1K
Annual income
$124.26/yr
Blended yield
0.54%
📊

Analyst Conviction Gap

Where Wall Street is split right now

BVNRY
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
6.6
Piotroski
8/9
NOBL
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BVNRY buys
0
NOBL buys
0
No recent congressional trades found for BVNRY or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBVNRYNOBL
Forward yield20.15%2.14%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%0%
Portfolio after 10y$23.3K$22.8K
Annual income after 10y$2.34$246.19
Total dividends collected$2.1K$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: BVNRY vs NOBL ($10,000, DRIP)

YearBVNRY PortfolioBVNRY Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$11,708$1,007.56$10,914$214.34+$794.00BVNRY
2$13,078$551.22$11,897$218.63+$1.2KBVNRY
3$14,282$287.74$12,952$222.72+$1.3KBVNRY
4$15,428$146.83$14,086$226.62+$1.3KBVNRY
5$16,582$74.12$15,302$230.33+$1.3KBVNRY
6$17,780$37.23$16,607$233.85+$1.2KBVNRY
7$19,043$18.65$18,007$237.18+$1.0KBVNRY
8$20,386$9.34$19,508$240.35+$878.00BVNRY
9$21,817$4.67$21,116$243.35+$701.00BVNRY
10$23,347$2.34$22,841$246.19+$506.00BVNRY

BVNRY vs NOBL: Complete Analysis 2026

BVNRYStock

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Full BVNRY Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this BVNRY vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BVNRY vs SCHDBVNRY vs JEPIBVNRY vs OBVNRY vs KOBVNRY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.